Np Life Sciences Health Industry Group Inc. (ACAT) intrinsic value & 10-year financials
Np Life Sciences Health Industry Group Inc. (ACAT) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 6 fiscal years revenue grew 39.9% a year to $164.6K, with an average return on invested capital of -68.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $10.00
- Market cap
- $429.6M
- Revenue (FY2023)
- $164.6K
- Revenue growth (6-yr CAGR)
- 39.9%
- ROIC (10-yr avg)
- -68.2%
- Free cash flow (FY2023)
- —
ACAT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2023 | $164.6K | -$2.9K | $0.00 | — | -0.4% | -3.9% |
| FY2022 | $102.0K | -$18.9K | $0.00 | — | -18.5% | -65.6% |
| FY2021 | $35.0K | -$65.7K | — | — | -187.7% | -92.5% |
| FY2020 | $15.0K | -$131.1K | — | — | -873.9% | -77.4% |
| FY2019 | $43.0K | -$108.8K | — | — | -253.2% | -101.6% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
NP Life Sciences Health Industry Group Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
NP Life Sciences Health Industry Group Inc. has historically struggled to out-earn its cost of capital, averaging just -68.2% ROIC.
NP Life Sciences Health Industry Group Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, NP Life Sciences Health Industry Group Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.00 per share.